View in EDS

METTL16 S-glutathionylation-triggered RNA m6A modification of IGF2BP3 inhibits CFTR expression and promotes chemoresistance in colorectal cancer.

Saved in:
Bibliographic Details
Title: METTL16 S-glutathionylation-triggered RNA m6A modification of IGF2BP3 inhibits CFTR expression and promotes chemoresistance in colorectal cancer.
Authors: Xu L; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.; State Key Laboratory of Quality Research in Chinese Medicine & Faculty of Chinese Medicine, Macau University of Science and Technology, Macao, 999078, China.; Department of Oncology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Xinhua Hospital of Zhejiang Province, Hangzhou, 310005, China., Ma Y; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China., Yao W; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China., Qiu YJ; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China., Xu C; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.; Department of Oncology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Xinhua Hospital of Zhejiang Province, Hangzhou, 310005, China.; Key Laboratory for Research on the Pathogenesis of 'Inflammation-Cancer Transformation' in Intestinal Diseases, Hangzhou, 310005, China.; Zhejiang Engineering Research Center of Intelligent Equipment of Chronic Chinese and Western Medicine, Hangzhou, 310005, China., Xu FY; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.; The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, China., Zou ZM; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.; Zhejiang Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, 310022, China., Dai WM; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.; Zhejiang Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, 310022, China., Gong WG; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China., Ma DN; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China., Chen XW; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.; Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, 310022, China., Ye WK; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.; The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, China., Huang YY; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.; The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, China., Chen HT; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.; Department of Oncology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Xinhua Hospital of Zhejiang Province, Hangzhou, 310005, China.; Key Laboratory for Research on the Pathogenesis of 'Inflammation-Cancer Transformation' in Intestinal Diseases, Hangzhou, 310005, China.; Zhejiang Engineering Research Center of Intelligent Equipment of Chronic Chinese and Western Medicine, Hangzhou, 310005, China., Hong L; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.; The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, China., Mo JP; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China., Feng JG; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.; Zhejiang Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, 310022, China., Yu EY; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China., Chen W; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China. chenwei@zjcc.org.cn.; Zhejiang Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, 310022, China. chenwei@zjcc.org.cn.; Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, 310022, China. chenwei@zjcc.org.cn., Zhang YH; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China. zhangyuhua1013@126.com.; The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, China. zhangyuhua1013@126.com., Yao QH; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China. 20234052@zcmu.edu.cn.; State Key Laboratory of Quality Research in Chinese Medicine & Faculty of Chinese Medicine, Macau University of Science and Technology, Macao, 999078, China. 20234052@zcmu.edu.cn.; Department of Oncology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Xinhua Hospital of Zhejiang Province, Hangzhou, 310005, China. 20234052@zcmu.edu.cn.; Key Laboratory for Research on the Pathogenesis of 'Inflammation-Cancer Transformation' in Intestinal Diseases, Hangzhou, 310005, China. 20234052@zcmu.edu.cn.; Zhejiang Engineering Research Center of Intelligent Equipment of Chronic Chinese and Western Medicine, Hangzhou, 310005, China. 20234052@zcmu.edu.cn., Li X; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China. lixia@zjcc.org.cn.; The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, China. lixia@zjcc.org.cn.; Zhejiang Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, 310022, China. lixia@zjcc.org.cn.; Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, 310022, China. lixia@zjcc.org.cn.
Source: Acta pharmacologica Sinica [Acta Pharmacol Sin] 2026 May 20. Date of Electronic Publication: 2026 May 20.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 100956087 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1745-7254 (Electronic) Linking ISSN: 16714083 NLM ISO Abbreviation: Acta Pharmacol Sin Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42162313
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: METTL16 S-glutathionylation-triggered RNA m<superscript>6</superscript>A modification of IGF2BP3 inhibits CFTR expression and promotes chemoresistance in colorectal cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Xu+L%22">Xu L</searchLink>; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.; State Key Laboratory of Quality Research in Chinese Medicine & Faculty of Chinese Medicine, Macau University of Science and Technology, Macao, 999078, China.; Department of Oncology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Xinhua Hospital of Zhejiang Province, Hangzhou, 310005, China.<br /><searchLink fieldCode="AU" term="%22Ma+Y%22">Ma Y</searchLink>; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.<br /><searchLink fieldCode="AU" term="%22Yao+W%22">Yao W</searchLink>; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.<br /><searchLink fieldCode="AU" term="%22Qiu+YJ%22">Qiu YJ</searchLink>; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.<br /><searchLink fieldCode="AU" term="%22Xu+C%22">Xu C</searchLink>; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.; Department of Oncology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Xinhua Hospital of Zhejiang Province, Hangzhou, 310005, China.; Key Laboratory for Research on the Pathogenesis of 'Inflammation-Cancer Transformation' in Intestinal Diseases, Hangzhou, 310005, China.; Zhejiang Engineering Research Center of Intelligent Equipment of Chronic Chinese and Western Medicine, Hangzhou, 310005, China.<br /><searchLink fieldCode="AU" term="%22Xu+FY%22">Xu FY</searchLink>; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.; The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, China.<br /><searchLink fieldCode="AU" term="%22Zou+ZM%22">Zou ZM</searchLink>; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.; Zhejiang Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, 310022, China.<br /><searchLink fieldCode="AU" term="%22Dai+WM%22">Dai WM</searchLink>; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.; Zhejiang Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, 310022, China.<br /><searchLink fieldCode="AU" term="%22Gong+WG%22">Gong WG</searchLink>; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.<br /><searchLink fieldCode="AU" term="%22Ma+DN%22">Ma DN</searchLink>; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.<br /><searchLink fieldCode="AU" term="%22Chen+XW%22">Chen XW</searchLink>; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.; Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, 310022, China.<br /><searchLink fieldCode="AU" term="%22Ye+WK%22">Ye WK</searchLink>; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.; The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, China.<br /><searchLink fieldCode="AU" term="%22Huang+YY%22">Huang YY</searchLink>; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.; The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, China.<br /><searchLink fieldCode="AU" term="%22Chen+HT%22">Chen HT</searchLink>; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.; Department of Oncology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Xinhua Hospital of Zhejiang Province, Hangzhou, 310005, China.; Key Laboratory for Research on the Pathogenesis of 'Inflammation-Cancer Transformation' in Intestinal Diseases, Hangzhou, 310005, China.; Zhejiang Engineering Research Center of Intelligent Equipment of Chronic Chinese and Western Medicine, Hangzhou, 310005, China.<br /><searchLink fieldCode="AU" term="%22Hong+L%22">Hong L</searchLink>; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.; The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, China.<br /><searchLink fieldCode="AU" term="%22Mo+JP%22">Mo JP</searchLink>; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.<br /><searchLink fieldCode="AU" term="%22Feng+JG%22">Feng JG</searchLink>; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.; Zhejiang Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, 310022, China.<br /><searchLink fieldCode="AU" term="%22Yu+EY%22">Yu EY</searchLink>; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.<br /><searchLink fieldCode="AU" term="%22Chen+W%22">Chen W</searchLink>; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China. chenwei@zjcc.org.cn.; Zhejiang Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, 310022, China. chenwei@zjcc.org.cn.; Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, 310022, China. chenwei@zjcc.org.cn.<br /><searchLink fieldCode="AU" term="%22Zhang+YH%22">Zhang YH</searchLink>; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China. zhangyuhua1013@126.com.; The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, China. zhangyuhua1013@126.com.<br /><searchLink fieldCode="AU" term="%22Yao+QH%22">Yao QH</searchLink>; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China. 20234052@zcmu.edu.cn.; State Key Laboratory of Quality Research in Chinese Medicine & Faculty of Chinese Medicine, Macau University of Science and Technology, Macao, 999078, China. 20234052@zcmu.edu.cn.; Department of Oncology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Xinhua Hospital of Zhejiang Province, Hangzhou, 310005, China. 20234052@zcmu.edu.cn.; Key Laboratory for Research on the Pathogenesis of 'Inflammation-Cancer Transformation' in Intestinal Diseases, Hangzhou, 310005, China. 20234052@zcmu.edu.cn.; Zhejiang Engineering Research Center of Intelligent Equipment of Chronic Chinese and Western Medicine, Hangzhou, 310005, China. 20234052@zcmu.edu.cn.<br /><searchLink fieldCode="AU" term="%22Li+X%22">Li X</searchLink>; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China. lixia@zjcc.org.cn.; The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, China. lixia@zjcc.org.cn.; Zhejiang Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, 310022, China. lixia@zjcc.org.cn.; Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, 310022, China. lixia@zjcc.org.cn.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100956087%22">Acta pharmacologica Sinica</searchLink> [Acta Pharmacol Sin] 2026 May 20. <i>Date of Electronic Publication: </i>2026 May 20.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group%22">Nature Publishing Group </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>100956087 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1745-7254 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216714083%22">16714083 </searchLink><i>NLM ISO Abbreviation: </i>Acta Pharmacol Sin <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42162313
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41401-026-01821-w
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: METTL16 S-glutathionylation-triggered RNA m6A modification of IGF2BP3 inhibits CFTR expression and promotes chemoresistance in colorectal cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Xu L
      – PersonEntity:
          Name:
            NameFull: Ma Y
      – PersonEntity:
          Name:
            NameFull: Yao W
      – PersonEntity:
          Name:
            NameFull: Qiu YJ
      – PersonEntity:
          Name:
            NameFull: Xu C
      – PersonEntity:
          Name:
            NameFull: Xu FY
      – PersonEntity:
          Name:
            NameFull: Zou ZM
      – PersonEntity:
          Name:
            NameFull: Dai WM
      – PersonEntity:
          Name:
            NameFull: Gong WG
      – PersonEntity:
          Name:
            NameFull: Ma DN
      – PersonEntity:
          Name:
            NameFull: Chen XW
      – PersonEntity:
          Name:
            NameFull: Ye WK
      – PersonEntity:
          Name:
            NameFull: Huang YY
      – PersonEntity:
          Name:
            NameFull: Chen HT
      – PersonEntity:
          Name:
            NameFull: Hong L
      – PersonEntity:
          Name:
            NameFull: Mo JP
      – PersonEntity:
          Name:
            NameFull: Feng JG
      – PersonEntity:
          Name:
            NameFull: Yu EY
      – PersonEntity:
          Name:
            NameFull: Chen W
      – PersonEntity:
          Name:
            NameFull: Zhang YH
      – PersonEntity:
          Name:
            NameFull: Yao QH
      – PersonEntity:
          Name:
            NameFull: Li X
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 20
              M: 05
              Text: 2026 May 20
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1745-7254
          Titles:
            – TitleFull: Acta pharmacologica Sinica
              Type: main
ResultId 1